Jul 5, 2025
Оfftopic Community
Оfftopic Community
Forums
New posts
Search forums
What's new
Featured content
New posts
New media
New media comments
New resources
New profile posts
Latest activity
Media
New media
New comments
Search media
Resources
Latest reviews
Search resources
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Install the app
Install
Forums
Information & News
RSS News
Health and Fitness
Older People With Chronic Leukemia May Benefit From Experimental Agent
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="tD33NAt" data-source="post: 2691632" data-attributes="member: 124445"><p>The experimental drug ibrutinib (PCI-32765) shows great promise for the treatment of elderly patients with chronic lymphocytic leukemia (CLL), according to interim findings from a clinical trial. The phase I/II trial, co-led by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) and MD Anderson Cancer Center, indicates that the oral agent has few side effects and a high one-year survival rate in older patients...<img src="http://feeds.feedburner.com/~r/mnt/healthnews/~4/ChTtE5u7SsE" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></p><p></p><p><a href="http://feedproxy.google.com/~r/mnt/healthnews/~3/ChTtE5u7SsE/245525.php" target="_blank">More...</a></p></blockquote><p></p>
[QUOTE="tD33NAt, post: 2691632, member: 124445"] The experimental drug ibrutinib (PCI-32765) shows great promise for the treatment of elderly patients with chronic lymphocytic leukemia (CLL), according to interim findings from a clinical trial. The phase I/II trial, co-led by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) and MD Anderson Cancer Center, indicates that the oral agent has few side effects and a high one-year survival rate in older patients...[IMG]http://feeds.feedburner.com/~r/mnt/healthnews/~4/ChTtE5u7SsE[/IMG] [url=http://feedproxy.google.com/~r/mnt/healthnews/~3/ChTtE5u7SsE/245525.php]More...[/url] [/QUOTE]
Insert quotes…
Name
Verification
Please enable JavaScript to continue.
Loading…
Post reply
Top